AI for protein design.
Pushing the limits.

Scroll Down

About us

From discovery to design.

We design it from day one, revolutionizing how protein therapeutics are developed.

At Galux, we develop a pioneering protein therapeutics design platform, GaluxDesign, that uniquely integrates
artificial intelligence and physical principles.

We bring your imagined proteins to life.

Our platform

GaluxDesign: Integrating physics into AI

Our proprietary AI platform is trained to design proteins from first principles,
resulting in its modality-agnostic nature.

Its unprecedented accuracy has been demonstrated through the de novo design
of antibodies, one of the most challenging protein classes to design.

Latest stories from Galux

GC Biopharma and Galux Collaborate on AI-designed Autoimmune Antibody Drugs
Read More
OliX and Galux Partner to Develop AI-based siRNA Delivery Platform
Read More
Galux to Present Preclinical Data on AI-Designed PD-1/IL-18v Immunocytokine at AACR 2026
Read More
Galux: Scaling AI-designed biologics
Read More
AI meets antibody design: Galux draws $29M series B for drug R&D
Read More
Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery
Read More

Join forces with Galux
to lead the next wave of drug innovation.
Together, we push boundaries
and redefine what's possible in medicine.

image